Life sciences briefing: Friday, Feb. 29, 2008
TODAY’S HEADLINES:
Arriva Pharma recaps with $6M for respiratory anti-inflammatory drugs (release)
Genetic tester Sciona gets another $5.2M, distribution deal (VentureWire)
Joint resurfacer Arthrosurface takes in $4M (release)
Automated medication dispenser MDG Medical receives $14M in debt, equity (release)
California Stem Cell raises funds for heart, neurodegenerative treatments (release)
Arriva Pharma recaps with $6M for respiratory anti-inflammatory drugs – Arriva Pharmaceuticals, an Alameda, Calif., drug developer focused on inflammatory respiratory disease, raised $6 million in a convertible-stock funding that recapitalized the company…. Continue Reading
Life sciences briefing: Tuesday, Feb. 5, 2008
TODAY’S HEADLINES:
Amira Pharma strikes GSK partnership on lung, heart drugs worth up to $425M (release)
Wolters Kluwer Health takes stake in Logical Images (release)
Gentiva Health acquires Home Health Care Affiliates for $55M (release)
Compuware buys Hilgraeve to upgrade healthcare IT (release)
Touchstone Health appoints Michael Muchnicki CEO (release)
Australia’s Xenome names Ian Nesbit as CEO (release)
Amira Pharma strikes GSK partnership on lung, heart drugs worth up to $425M – Amira Pharmaceuticals, a San Diego biotech focused on drugs for lung… Continue Reading
Life sciences briefing: Wednesday, Oct. 31, 2007
Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals
UPDATED: Expanded items on Harmony Info, SymBio Pharma and Merrion Pharma, added Dicerna item.
UPDATE REDUX: Added Syntaxin item.
U.K. biotech Syntaxin raises £16M for pain and nervous-system drugs — Syntaxin, a U.K. biotech focused on drugs that affect cell secretion, raised £16 million ($33.2 million) in a second funding round. The company’s release is here.
Investors in the round included SR One, the venture capital… Continue Reading
Life sciences briefing: Thursday, Sept. 6, 2007
Featured companies: Cyntellect, Lectus Therapeutics, NeoMatrix, Nexstim, Pearl Therapeutics, Proteon Therapeutics, SupplyScape
(UPDATED at 10am PT: See below.)
Airway-disease specialist Pearl Therapeutics raises $15.5M — Redwood City, Calif.-based Pearl Therapeutics, a drug-formulation company focused on respiratory disease, raised $15.5 million in a first funding round. Investors included New Leaf Ventures, Clarus Ventures and 5AM Ventures.
Pearl doesn’t appear to have a working Web site yet, but according to its release, the company aims to treat unspecified airway diseases using “particle… Continue Reading